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Immune Checkpoints in Cancer Treatment
Abstract
Despite the human immune system, cancer thrives in an extremely hostile environment. Cancer is the second
most common cause of death in the U.S. with about 600,000 deaths every year, and cancer is expected to
surpass heart disease as the most common cause of death in the U.S. Immune checkpoint inhibitors are a
novel and promising therapeutic for treating cancer in its late stages.
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Despite the human immune system, cancer thrives in an extremely hostile 
environment.  Cancer is the second most common cause of death in the 
U.S. with about 600,000 deaths every year, and cancer is expected to 
surpass heart disease as the most common cause of death in the 
U.S. Immune checkpoint inhibitors are a novel and promising therapeutic 
for treating cancer in its late stages. 
Overview
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Treatment Information
Background
The human immune system evolved to detect and 
respond to antigens, or foreign insults. When a cell 
detects an antigen from within, through a series of 
events, the cell presents the antigen to the immune 
system via a major histocompatibility complex type I 
(MHCI). Most of the time, MHCs are non-presenting. 
When in this state, the immune system cannot detect 
foreign insults, thus the immune system does not 
mount an immune response. For example, when MHCI 
is non-presenting, a T cell receptor (TCR) will not bind 
to MHCI, thus no interaction occurs (see Figure 
1.). For a long time, many researchers hypothesized 
that transformed cells, cancerous cells derived from 
within normal cells, used the host cell to disguise its 
insult from the immune system. Researchers now 
believe that in many cases, 
this hypothesis is false.
The invention of ipilimumab, the first successful immune checkpoint 
inhibitor, marked the inception of a new era in cancer treatment.  
Immune checkpoint inhibitors like ipilimumab and nivolumab (anti-PD-
1) block the immune suppression pathway by mimicking the 
suppression ligand that binds to either PD-1 or CTLA-4 (see Figure 
3.). The binding of these antibodies is irreversible, thus allowing the 
bonded CTL to be uninterrupted as it carries out instructions from the 
costimulatory pathway. The resulting clonal expansion of CTLs specific 
to the cancer antigen leads to a robust immune response to the 
cancer cells. The randomness of which molecules bump into other 
molecules is a critical component to the success or failure of immune 
checkpoint cancer treatments. After all, both PD-L1 and CD80/CD86 
and their mimicking antibodies bind irreversibly to their respective PD-
1 or CTLA-4. Although several minor factors influence the probability 
that a protein will meet its ligand, the process is largely random. For 
the purpose of simplicity, the actual probabilities can be adequately 
represented by a random system. In order to best understand this 
situation, consider Figure 3. mathematically.
Given 1 PD-1, 1 PD-L1, and 4 anti-PD-1, what is the probability that 
the immune suppression pathway will be blocked? What is the 
probability that the pathway will be active?
PD-1 may bind to PD-L1 to activate the immune suppression pathway, 
or it may bind to one of the four anti-PD-1 ligands to block the 
pathway.
4 block / 5 total = 0.8 block
1 activate / 5 total = 0.2 active
In an environment with many transformed cells, some are likely to 
survive. The daughter cells of the survivors do not inherit PD-1, and 
are thus vulnerable to the effect of the drugs.
While this treatment shows promise by hindering cancer, it is very 
unlikely to cure cancer. Figure 4. illustrates a cancer cell’s common 
and rapid adaptation to its new, hostile environment. Again, 
mathematics can be used to easily visualize the significance of the 
situation.
Given 1 PD-1, 30 PD-L1, and 4 anti-PD-1, what is the probability that 
the immune suppression pathway will be blocked? What is the 
probability that the pathway will be active?
PD-1 may bind to one of the thirty PD-L1 to activate the immune 
suppression pathway, or it may bind to one of the four anti-PD-1 
ligands to block the pathway.
4 block / 34 total = 0.1 block 
30 activate / 34 total = 0.9 active
Clearly, the adaptation is devastating to the success of anti-PD-1. In 
most cases, the adaptation is likely caused by a specific aneuploidy 
rather than by mutation, which would explain both its relatively large 
frequency and short lag time. Cancer cells without the adaptation are 
likely to die. Cancer cells with the adaptation are likely to survive. The 
drugged environment selects for cells with the adaptation and against 
the cells without the adaptation. This selection results in a bottleneck 
effect. Most survivors emerge resistant to the new environment, and 
their unhindered cell division leads to large populations of resistant 
cancer cells.
Treatment Mechanism
Many immune checkpoint inhibitors are in clinics and development today.  
These inhibitors extend the life of a terminally ill patient or serve as a 
safeguard accompanying removal of cancerous tissue. Ipilimumab and 
nivolumab are most often used to extend life by treating late stage, 
metastatic melanoma and lung cancer. In a study, ipilimumab plus 
dacarbazine (a chemotherapeutic) were found to have a five-year survival 
rate of 18.2% versus the 8.8% five-year survival rate of placebo plus 
dacarbazine (see Figure 5.). Nivolumab and other immune checkpoint 
inhibitors offer similar results for their respective cell types. All approved 
immune checkpoint inhibitors have around a 20% five-year survival rate.  
Inhibitor cocktails can sometimes lead to better results at the cost of higher 
toxicity.
Figure 5. Phase III study compares the living proportion treated with 
ipilimumab plus dacarbazine (blue) and the living proportion treated 
with placebo plus dacarbazine (yellow), both vs. months elapsed. 
Symbols indicate censored observations. n=247, n=251.
Bristol-Myers Squibb is a major company in the development of these 
immune checkpoint inhibitors.  Bristol-Myers Squibb prices ipilimumab 
(brand name YERVOY) at $30,000 per dose. Each dose consists of 
3mg/kg every three weeks. A regimen typically consists of four consecutive 
doses, which brings the total cost of treatment to $120,000; however, a 
patient-assistance program may reduce the price to $80,000. All immune 
checkpoint inhibitors cost around $150,000 for one year of treatment. The 
medication is administered regularly until progression of the disease or 
until toxicity becomes intolerable. 
In cancer patients, the immune 
system often detects the insult by 
recognizing a cancer antigen in 
MHCI. A cytotoxic T lymphocyte 
(CTL), a staple component of the 
acquired immune response, binds 
to the antigen-presenting MHCI at 
the TCR. Cytokines, small 
molecules that assist in immune 
responses, facilitate the formation 
of a costimulatory pathway. 
Different cell types carry different 
surface proteins and ligands. Two 
such sets of surface protein and 
ligand are shown in Figure 2. The 
study of how these pathways form 
is an active research area. The 
CD80/CD86 and CD28 
costimulatory pathway is as 
necessary as the MHCI and TCR
Figure 1. No interaction between a normal, 
untransformed cell and a cytotoxic T cell.
Figure 2. Immune response suppressed 
by immune suppression pathway.
pathway. This costimulatory pathway, referred to as the cell proliferative 
pathway, signals the cytotoxic T cell to clonally expand to around 10^15 
copies. If created, all of these copies would be programmed with the 
directive to kill cancer cells bearing a cancer antigen. However, cancer 
cells make use of the suppression pathway to silence instructions from the 
costimulatory pathway. 
One suppression pathway is the PD-L1 and PD-1 pathway. When both 
pathways are simultaneously delivering instructions to the CTL, the CTL 
becomes inactive or dies. In addition to dominance, when both pathways 
are active CD80/CD86 of the suppression pathway sometimes (if bonding 
attractions are strong enough) has the ability to break the costimulatory 
pathway in a process called transendocytosis.
Figure 3. Immune response enabled by blocking 
of the immune suppression pathway.
Figure 4. Immune response suppressed by 
immune suppression pathway, despite 
immune checkpoint cancer treatment.
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Conclusions
Immune checkpoint inhibitors, such as ipilimumab and nivolumab, block 
the suppression pathway of cancer cell interaction with T cells.  This 
mechanic stimulates the proliferation of T cells, which can result in a 
robust immune response to metastatic melanoma, among other cancers.  
Immune checkpoint inhibitors tend to produce around a 20% five-year 
survival rate.
